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ABSTRACT
Background Evidence suggests that lamotrigine could 
be effective in reducing aura frequency and duration. 
However, studies comparing lamotrigine to other, first- line 
prophylactic agents solely involving patients suffering from 
migraine with aura are still lacking. The aim of this study 
was to compare the efficacy of lamotrigine and topiramate 
for the preventive treatment of migraine with aura.
Methods Fifty- three patients suffering from migraine with 
aura treated with lamotrigine or topiramate for at least 6 
months were included. Pre- and post- treatment clinical 
data regarding monthly aura frequency and duration, 
monthly migraine frequency, days of headache and rescue 
medication used per month were collected.
Results Responder rates were similar between the two 
treatment groups at 6- month follow- up. Interestingly, 
responder rates for aura frequency and duration were 
higher in the lamotrigine group compared with the 
topiramate group (88% vs 79% and 73% vs 54%). 
Moreover, 50% of the lamotrigine- treated patients reported 
a complete disappearance of migraine aura compared 
with 37% of topiramate- treated patients. Side effects 
were more frequent in topiramate group compared with 
lamotrigine group (p=0.004).
Conclusions Lamotrigine should be considered in clinical 
practice for the preventive treatment of migraine with 
aura especially for patients reporting prolonged aura and 
who do not respond, have contraindications or discontinue 
topiramate treatment due to side effects.
INTRODUCTION
Migraine is a common disabling neurolog-
ical disorder, characterised by unilateral, 
pulsating, severe headache attacks, frequently 
associated with autonomic symptoms such as 
nausea, vomiting, photophobia and phono-
phobia. In approximately 30% of cases, 
migraine is preceded by or associated with 
transient, reversible, focal neurological symp-
toms called aura,1 which develops gradually 
over 5–20 min and usually lasts for less than an 
hour.2 The most common aura symptoms are 
visual and sensory ones, followed by language, 
motor and brainstem disturbances.3
Pathophysiology of migraine aura has 
been linked to cortical spreading depression 
(CSD), which consists in a self- propagating 
wave of depolarization, followed by a more 
slowly- propagating wave of neuronal inhibi-
tion usually developing within the occipital 
cortex and then spreading throughout more 
anterior cortical areas at a speed of 3–6 mm/
min.4 According to experimental models, 
CSD is characterised by changes in extracel-
lular potassium concentrations and neuronal 
glutamate release, which determine the prop-
agation of the depolarization wave.5 Perfu-
sion weighted and functional MRI studies 
showed a causal relationship between CSD 
and aura within human visual cortex high-
lighting CSD causative role in determining 
the aura phenomenon.6–8
Latest evidence suggests that CSD can also 
determine meningeal nociceptor firing, thus 
leading to the activation of the trigemino- 
vascular system which has been linked to 
the development of migraine headache.9 
However, the relationship between CSD and 
migraine headache is not fully understood 
yet.
Recent developments in the understanding 
of migraine pathophysiology have led 
researchers to investigate new targeted ther-
apeutic approaches for the treatment of the 
disease. Data from randomised, controlled 
trials exploring the efficacy of monoclonal 
antibodies for the treatment of migraine 
showed promising results and would prob-
ably change the management and the clinical 
outcome of patients affected by episodic and 
chronic migraine in the next years.10 Never-
theless, clinical management of migraine with 
aura remains extremely uncertain for neurol-
ogists since preventive treatments showing a 
clear efficacy in reducing aura frequency and 
duration are still lacking. In fact, currently 
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approved first- line agents for migraine prophylaxis, 
showed little or no benefit for the preventive treatment 
of migraine with aura.11
Lamotrigine is an antiepileptic, sodium channel 
blocking drug able to induce an indirect inhibition of 
neuronal glutamate release thus blocking CSD propaga-
tion throughout the cerebral cortex as shown by experi-
mental model of CSD.12 The role of lamotrigine for the 
preventive treatment of migraine has been previously 
investigated. A double- blind, randomised,controlled, 
crossover study involving suffering from migraine with 
and without aura, concluded that lamotrigine was inef-
fective in reducing migraine frequency and intensity 
compared with topiramate, another antiepileptic drug 
approved as first- line agent for migraine prophylaxis,13 
although efficacy outcomes of patients solely affected 
by migraine with aura were not reported at the end of 
the abovementioned study. On the other hand, evidence 
suggests that lamotrigine could be effective within the 
migraine aura clinical setting.14–16 To our best knowledge, 
studies comparing lamotrigine to others, first- line prophy-
lactic migraine agents involving a population of patients 
solely suffering from migraine with aura are still lacking. 
For this reason, we conducted a retrospective analysis in 
order to assess the efficacy of lamotrigine compared with 
topiramate for the preventive treatment of migraine with 
aura.
MATERIAL AND METHODS
We reviewed the clinical records of 1152 patients referred 
to our Headache Clinic from January 2014 to February 
2019. Inclusion criteria for the enrolment were: a diag-
nosis of migraine with aura or aura without migraine 
according to the last Headache International Society 
diagnostic criteria;2 aged≥18 years; migraine onset before 
the 50 years of age; presence of migraine attacks for at 
least 1 year prior to entering the study; at least two attacks 
of migraine with aura or aura without migraine per 
month in the previous 3 months. Exclusion criteria were: 
any other non- migraine headache; chronic headache 
defined as more than 15 headache days per month; coex-
istence of medication overuse headache; any other severe 
co- morbid medical condition (e.g. cardiac, hepatic, renal 
and psychiatric disease); other preventive migraine treat-
ments in the last 3 months prior to entering the study; 
previous failure of more than two prophylactic agents. 
Patients allocation to topiramate or lamotrigine treatment 
was based on neurologist’s clinical judgement, taking into 
account patient clinical scenario, possible contraindica-
tions to the drugs, previous ineffective preventive treat-
ments as well as patient preferences.
A total of 53 patients were recruited, 25 of whom treated 
with topiramate and 28 with lamotrigine. Nine patients 
within the topiramate group and six patients within the 
lamotrigine group also reported migraine without aura 
attacks. Finally, one patient affected by aura without 
migraine was also included, who had been treated with 
topiramate. Local ethics committee waived the need for 
approval and the need to obtain consent for the collec-
tion, analysis and publication of the retrospectively 
obtained and anonymized data for this study.
According to clinical records, all patients had normal 
extensive laboratory findings, including workup for an 
underlying coagulopathy. Furthermore, all of them have 
previously undergone MRI brain scan in order to exclude 
secondary cause of headache. Treatment dosage varied 
between 25 mg two times a day and 100 mg two times a 
day both for topiramate and lamotrigine, according to 
clinical judgement. Treatments were gradually started in 
order to reduce development of side effects. All patients 
were followed for a period of at least 6 months after 
starting treatment. Reassessment took place on ambula-
tory visit or on phone interviews conducted by trained 
examiners. Data collection was based both on patient 
self- reporting and on examination of headache diary. 
We evaluated responder rates, defined as the percentage of 
patients reporting a reduction of at least 50% of migraine 
with aura attacks at the end of the follow- up period, 
and optimal responder rates, defined as patient reporting a 
complete disappearance of migraine with aura attacks at 
6 month follow- up. We further evaluate the pre- to post- 
treatment change of monthly (28 days) aura frequency, 
aura duration per episode (minutes), monthly (28 days) 
migraine frequency, monthly days of headache and rescue 
medication used per month between the two treatment 
groups. Finally, dropout rate and type and frequency of 
side effects for both treatment groups were reported.
STATISTICAL ANALYSIS
Statistical analysis was performed using SPSS V.20 
(SPSS, Chicago, Illinois, USA). A Shapiro- Wilk’s test (W 
statistic=0.74; p=0.001) and a visual inspection of histo-
grams, normal Q- Q plots and box plots showed that 
samples pretreatment data for all the variables taken into 
account were not normally distributed for both treatment 
groups. Pretreatment descriptive statistics for both groups 
and pre- to post- test analysis were then performed using 
non- parametric tests. We used the Mann Whitney U test 
for continuous variables and the χ² test for nominal and 
ordinal variables. A two- tailed p value was calculated for 
each test. A significance level of <0.05 was set.
RESULTS
Of the 53 patients recruited, 25 (3 male/22 female) were 
treated with topiramate and 28 (3 male/25 female) with 
lamotrigine. Among the two treatment groups, only one 
patient affected by aura without migraine was included, 
who had been treated with topiramate. Demographics 
and baseline clinical characteristics of both treatment 
groups are detailed in table 1.
Clinical features and distribution of migraine aura 
within the study population are reported in table 2.
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Groups were sex- but not age- matched, since lamotrigine- 
treated patients were younger than those treated with 
topiramate (median age 37 and 46 years, respectively). 
There was no difference in age of migraine onset between 
the two groups. Interestingly, among lamotrigine- treated 
patients, 71% (20/28) had been previously treated with 
at least another migraine prophylactic agent compared 
with 48% (12/25) of those within the topiramate group, 
although this difference was not statistical significant, as 
shown in table 1.
Median prescribed dosage was 50 mg two times a day for 
both lamotrigine and topiramate (range 25 mg two times 
a day to 100 mg two times a day). Two patients treated 
with lamotrigine and one patient treated with topira-
mate discontinued treatment after few days due to severe 
side effects and were therefore excluded from outcome 
analysis.
Responder rates and optimal responder rates for 
monthly aura frequency, aura duration per episode and 
monthly migraine frequency are detailed in table 3.
Both lamotrigine and topiramate were highly effec-
tive in reducing monthly migraine frequency of at least 
50% at the end of the follow- up period and no substan-
tial difference between the two treatment groups was 
reported. Responder rates for aura frequency and 
duration were higher in the lamotrigine group compared 
with the topiramate group (88% vs 79% and 73% vs 54%, 
respectively), although these differences failed to reach 
statistical significance.
Similarly, optimal responder rates, defined as patient 
reporting a complete disappearance of migraine attacks 
and migraine aura, tended to be higher in lamotrigine 
compare to topiramate- treated patients (27% vs 13% and 
50% vs 37%, respectively).
We further evaluated pre- to post- treatment changes 
between the two groups for all the parameters taken into 
account (table 4).
While change in monthly migraine frequency, number 
of migraine days and rescue medication used per month 
were comparable between the two treatment groups, 
a slightly more pronounced reduction of monthly aura 
frequency was found within the lamotrigine group 
compared with the topiramate group.
Interestingly, lamotrigine showed to reduce aura dura-
tion per episode of 15 min while topiramate show no rele-
vant efficacy in reducing this parameter (p=0.062).
As mentioned above, two patients within the lamo-
trigine group and one patient within the topiramate 
group discontinued treatment after few days due to severe 
Table 1 Demographics and baseline clinical characteristics of study population
Topiramate Lamotrigine P value (<0.05)
Sex (M/F) (%) 3/22 (12/88) 3/25 (11/89) 0.60
Median age (years, range) 46 (23–66) 37 (18–84) 0.021
Median age of migraine onset (years, 
range) 18 (6–48) 15.5 (6–38) 0.058
Prior preventive treatment (%yes/%no) 12/25 (48/52) 20/28 (71/29) 0.082
Median Range Median Range
Aura episodes per month 4 1–15 4.5 1.5–15 0.18
Duration of aura episodes (min) 28 5–90 30 5–90 0.44
Migraine attacks per month 7 2.5–15 5 1.5–15 0.15
Days of migraine per month 9 1.8–15 7.5 1.8–15 0.35
Rescue medication used per month 10 2.5–15 9 1.5–15 0.51
Table 2 Clinical characteristics and distribution of migraine 
aura within the two treatment groups
Frequency Per cent
Topiramate
  Visual 23 92
  Visual and sensory 2 8
Lamotrigine
  Visual 20 71
  Hemiplegic 1 3
  Visual and sensory 4 14
  Visual, sensory and 
aphasic
3 10





  Aura frequency 19/24 (79%) 23/26 (88%) 0.37
  Aura duration 13/24 (54%) 22/26 (73%) 0.16
  Migraine 
frequency
20/23 (87%) 17/26 (85%) 0.81
ORRs
  Aura 9/24 (37%) 13/26 (50%) 0.37
  Migraine 3/23 (13%) 7/26 (27%) 0.22
ORRs, optimal responder rates; RRs, responder rates.
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side effects (rash for lamotrigine and cognitive symptoms 
for topiramate). Patients who continued both treatments 
reported only mild side effects. Within the topiramate 
group, the most frequent side effects reported were tran-
sient paresthesia, weight loss, dizziness, somnolence and 
cognitive symptoms such as concentration/attention 
difficulties, slow- thinking and mood changes. Among 
the lamotrigine- treated patients, the most reported side 
effects were fatigue, anxiety, somnolence and nausea (see 
table 5 for details). Side effects were significantly more 
frequent within the topiramate group compared with the 
lamotrigine group (p=0.004).
DISCUSSION
The aim of our study was to explore the role of lamo-
trigine for the prevention of episodic migraine with 
aura. For this purpose, we decided to compare lamo-
trigine to topiramate, an antiepileptic drug established 
to be highly effective for the preventive treatment of 
episodic migraine.17 Pooled data from three large multi-
centre, double- blind, placebo- controlled trials demon-
strated a clinically relevant response of monthly migraine 
frequency in patients treated with topiramate compared 
with placebo and led to topiramate approval as first- 
line drug for migraine prophylaxis.18 Further studies 
confirmed a similar efficacy of topiramate compared 
with other first- line prophylactic drugs such as propran-
olol and valproate.19 Real- world experience with topira-
mate proved its efficacy in reducing migraine frequency, 
improving patient quality of life and social functioning as 
well as reducing healthcare resources allocation to head-
ache,20 making topiramate one of the most used migraine 
preventive drug in clinical practice nowadays. More-
over, due to its mechanism of action, topiramate is also 
believed to affect migraine aura initiation.21 In an exper-
imental model of CSD, topiramate showed to inhibit 
the propagation of induced CSD in a dose- dependent 
manner.22 However, its clinical efficacy in preventing 
migraine aura is not clear. In an open longitudinal, pilot 
study involving patients affected by migraine with aura, 
topiramate failed to reduce aura frequency and duration 
at 6- month follow- up. Additionally, a posthoc analysis of 
the PROMPT trial, a well- designed study consisting of an 
open label phase in which patients were treated with topi-
ramate for 26 weeks, followed by a double- blind phase 
in which patients were randomized to receive placebo 
or continue to receive topiramate, showed a significant 
reduction in migraine aura frequency at the end of the 
open label phase which was maintained throughout the 
double- blind phase.23 However, no significant change in 
number of auras between topiramate and placebo were 
found at the end of the follow- up period.24
Contrary to topiramate, the role of lamotrigine in the 
prevention of migraine is more controversial.
The North American guidelines for the preventive 
treatment of episodic migraine included lamotrigine 
among medications established to be ineffective.17 This 
low level of grading is essentially based on the results of 
Table 4 Pre- to post- treatment changes between the two groups at follow- up
Topiramate Lamotrigine P value 
(<0.05)Mdn IQR Mdn IQR
Aura frequency per month −2.4 3.4 −4 3.9 0.28
Duration of aura episodes (min) −2.5 15 −15 19 0.062
Migraine attacks per month −4.5 8 −3.7 6.6 0.10
Days of migraine per month −6 3 −4.7 5.3 0.37
Rescue medication used per month −5.5 5.5 −5.5 6.6 0.44
IQR, interquartile range; Mdn, median.
Table 5 Side effects and dropout rate between the two treatment groups
Topiramate Lamotrigine
P value (<0.05)N % N %
Overall 15/25 60 6/28 21 0.004
Weight loss 6/25 24
Transient paresthesia 9/25 36
Cognitive symptoms 7/25 28 1/28 4
Somnolence 2/25 8 1/28 4
Fatigue 1/28 4
Rash 2/28 7
Dropout due to side effects 1/25 4 2/28 7 0.621
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two prospective, randomized, controlled trials, involving 
migraineurs both with and without aura. Both studies 
failed to demonstrate the efficacy of lamotrigine in 
migraine prophylaxis compare to placebo and topira-
mate respectively.13 25 However, posthoc analysis from 
the abovementioned studies, exploring the role of lamo-
trigine in reducing migraine aura frequency, was not 
conducted due to the small number of patients suffering 
from migraine with auraincluded. Lamotrigine is an 
antiepileptic drug that exerts its function by blocking 
voltage- sensitive sodium channels, indirectly leading 
to the inhibition of neuronal release of glutamate, a 
neurotransmitter involved in the development and prop-
agation of CSD. Evidence suggests that chronic intraper-
itoneal administration of lamotrigine determine a strong 
suppression of CSD propagation in rats compared with 
placebo and valproate.12 More than a decade ago, several 
pilot, open label studies exploring the role of lamotrigine 
in the prophylaxis of migraine aura were conducted 
and pointed to a great efficacy of the drug in reducing 
both frequency and duration of aura episodes.14–16 Based 
on these findings, a prospective open study including 
59 patients suffering from migraine with aura treated 
with lamotrigine showed a sustained reduction of aura 
frequency and duration. Additionally, more than three 
quarters of the aura responder patients also reported 
a significance reduction of migraine attacks frequency 
during the treatment period, suggesting a potential effi-
cacy of lamotrigine for the prophylaxis of migraine head-
ache as well.26 Based on these results, lamotrigine is largely 
used in clinical practice for the preventive treatment of 
migraine with aura especially in patients for whom other 
preventive treatments are ineffective or contraindicated, 
although clear evidence supporting the non- inferiority 
of lamotrigine compared with other approved migraine 
prophylactic agents is still lacking.
Our study is the first to compare the efficacy of lamo-
trigine and topiramate in solely patients suffering from 
migraine with aura. Both treatments showed to equally 
reduce monthly frequency of migraine attacks at 6 
months of follow- up. Consequently, our results suggest 
a similar efficacy of both treatments within the clinical 
setting of migraine with aura. Interestingly, the majority 
of lamotrigine- treated patients included in our study had 
been previously treated with at least another migraine 
prophylactic agent, suggesting that the therapeutic effect 
of lamotrigine was certainly not obtained in a popu-
lation of less resistant patients. Additionally, despite a 
well- established tolerability profile, discontinuation rates 
due to adverse events associated with topiramate are 
higher in patients with migraine compared with patients 
with epilepsy.27 Although the small number of patients 
included in our study, our tolerability data showed a 
significantly higher rate of adverse events within topira-
mate group compared with lamotrigine- treated patients.
Finally, according to the North American Antiepi-
leptic Drug pregnancy registry, topiramate showed a 
dose independent threefold higher risk of congenital 
malformations and child developmental retardation 
in women exposed to the drug, especially in the first 
trimester of pregnancy.28 On the other hand, teratogenic 
activity of lamotrigine is dose- dependent and exerted at 
higher dosage than that used for migraine prophylaxis.29 
Based on our findings, lamotrigine should be considered 
in clinical practice for patients having migraine with aura 
reporting unresponsiveness to topiramate treatment or 
who discontinue the drug due to side effects. Moreover, 
lamotrigine could be safely offered to patients who have 
contraindications to topiramate, especially migraine with 
aura women planning to have pregnancy.
Regarding the effects on aura frequency and dura-
tion, our results showed a trend towards a better efficacy 
of lamotrigine compared with topiramate. Responder 
rates for monthly aura frequency were similar between 
the two treatment groups. However, approximately half 
of the lamotrigine- treated patients reported a complete 
disappearance of aura at 6- month follow- up. Additionally, 
lamotrigine determined a reduction of aura duration per 
episode of approximately 15 min. In line with previous 
findings,16 lamotrigine should then be considered in clin-
ical practice for the treatment of prolonged or disturbing 
migraine with aura. We are aware of several limitations of 
this study. A possible bias in patients’ selection, the small 
number of patients recruited, the absence of a placebo 
controlled group and the retrospective nature of our 
study may have indicated a higher efficacy of both drugs 
than observed in other studies. Although results similar 
to ours for lamotrigine have been previously reported 
by Pascual et al16 with a retrospective, non- placebo- 
controlledì analysis, we think that the main result of our 
study was not the demonstration of the effectiveness of 
any specific drug, rather the evidence of a similar effec-
tiveness of lamotrigine compared with topiramate. This 
could open new therapeutic possibilities, especially in 
patients for whom topiramate is contraindicated or who 
are intolerant to this drug. We hope that our observation 
may stimulate further prospective, double- blind, random-
ized, controlled trials to prove the role of lamotrigine in 
the prophylaxis of migraine with aura.
CONCLUSION
Lamotrigine is equally effective as topiramate for the 
preventive treatment of migraine with aura and exhibits a 
better tolerability profile. Lamotrigine should be consid-
ered in clinical practice especially for patients reporting 
prolonged aura and who do not respond, have contra-
indications or discontinue topiramate treatment due to 
side effects.
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